Translational and clinical development at TPD Summit 2026
Oct 26–29, 2026 Boston, MA ~300 attendees Website
17 organizations at TPD Summit 2026 present work in translational & clinical development: 16 drug developers and 1 technology or service provider. Between them they bring 24 presentations to the program. Most represented: Nurix Therapeutics (4 on the program), Astellas (2 on the program), Arvinas (2 on the program). 6 of them have their own page in this guide. As of Oct 20, 2026.
Format
Top represented
Showing 1–17 of 17 organizations
| Organization | TPD Summit 2026 Attendance |
|---|---|
Nurix Therapeutics San Francisco, CA | ◇Industry Partner |
Clinical-stage biotech developing targeted protein degraders, including BTK degraders, for cancer and inflammatory diseases. | Panel Tue Oct 27 9:00am Navigating the Evolving Induced Proximity Landscape: Trends, Opportunities & Global Impact Investment, partnering & strategy Talk Tue Oct 27 12:30pm Panel Wed Oct 28 10:00am Shaping Investment in Induced Proximity: Insights to Accelerate Development & Secure Funding Investment, partnering & strategy Talk Thu Oct 29 9:00am Session Details to be Announced AI & computational design |
Astellas Tokyo, Japan | ◇Industry Partner |
Japanese pharmaceutical company with a targeted protein degradation program, including the KRAS G12D degrader setidegrasib. | Talk Tue Oct 27 2:00pm Talk Wed Oct 28 3:00pm |
Arvinas New Haven, CT | |
Biotech developing PROTAC protein degraders for cancer and neurological diseases. | Talk Tue Oct 27 8:30am Degradation Delivered – What the First TPD Approval Means for the Future of the Field Translational & clinical developmentInvestment, partnering & strategy |
Develops targeted protein degraders that disrupt cancer cell fitness, including the PIP4K2C degrader LRK-4189. | Panel Tue Oct 27 9:00am Navigating the Evolving Induced Proximity Landscape: Trends, Opportunities & Global Impact Investment, partnering & strategy |
Develops targeted protein degraders that use a new E3 ligase, aiming to reduce hematologic toxicity. | Talk Tue Oct 27 12:30pm |
Biodesix Louisville, CO | ◇Program Partner |
Lung disease diagnostics company with Medicare-covered tests that offers biopharma partners biomarker development and laboratory testing services. | |
Biotech developing cancer therapies that target cell state, including an oral KAT2A/B degrader for blood cancers. | |
AUTOTAC Bio Seoul, South Korea | |
Korean biotech whose AUTOTAC platform clears proteins and aggregates through autophagy; ATB2005A targets tau aggregates in the clinic. | |
BioTheryx San Diego, CA | |
Biotech developing protein degraders, including the CDK4/6 degrader BTX-9341 for breast cancer. | Talk Wed Oct 28 9:00am |
Bristol Myers Squibb Princeton, NJ | |
Global pharmaceutical company with medicines in oncology, immunology, cardiovascular disease and neuroscience, and a protein degrader pipeline. | |
Develops bispecific antibodies that selectively degrade disease-causing extracellular and membrane proteins. | |
Kymera Therapeutics Watertown, MA | |
Clinical-stage biotech developing oral small-molecule protein degraders, mainly for immunology and inflammation. | Talk Wed Oct 28 12:00pm |
Neomorph San Diego, CA | |
Develops molecular glue degraders, including NEO-811 against ARNT for kidney cancer. | |
Develops KRAS degraders for hard-to-treat cancers. | |
Develops RapaGlues, non-degrading molecular glues aimed at hard-to-drug targets. | |
Designs molecular glue degraders that use a broad range of E3 ligases, in oncology and other diseases. | Talk Wed Oct 28 11:30am |
Takeda Tokyo, Japan | |
Global pharmaceutical company developing medicines in gastroenterology, rare diseases, neuroscience, oncology and plasma-derived therapies. |
Instantly find 20 buyers in translational & clinical development
Get a list of who you should contact, their contact info, and what to say.
Totally free and instant, no sign up necessary!
Browse TPD Summit 2026 by
Organization type
Topic
Everyone
Not affiliated with or endorsed by the TPD & Induced Proximity Summit or its organizers. Submit a correction